{
    "id": 28312,
    "fullName": "ALK I1179V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ALK I1179V lies within the protein kinase domain of the Alk protein (UniProt.org). I1179V has been demonstrated to occur as a secondary drug resistance mutation in the context of ALK compound mutations (PMID: 29650534), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "I1179V",
    "createDate": "06/08/2018",
    "updateDate": "09/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 176037,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29220816T>C",
        "cDna": "c.3535A>G",
        "protein": "p.I1179V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14077,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK I1179V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29931,
                "profileName": "EML4 - ALK ALK I1179V ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29930,
            "profileName": "ALK I1179V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29931,
            "profileName": "EML4 - ALK ALK I1179V ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 176037,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29220816T>C",
            "cDna": "c.3535A>G",
            "protein": "p.I1179V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}